DNA-based therapeutics and DNA delivery systems: A comprehensive review
Tóm tắt
Từ khóa
Tài liệu tham khảo
Crooke ST. An overview of progress in antisense therapeutics.Antisense Nucleic Acid Drug Dev. 1998;8:115–122.
Stull RA, Szoka FC Jr. Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.Pharm Res. 1995;12:465–483.
Patil SD, Burgess DJ. DNA-based Biopharmaceuticals: therapeutics for the 21st Century.AAPS Newsmagazine 2003;6(12):27.
Baker BF. The role of antisense oligonucleotides in the wave of genomic information.Nucleosides Nucleotides Acids, 2001;20(4–7):397–399.
Van Ommen GJB, Bakker E, Den Dunnen JT. The human genome project and the future of diagnostics, treatment, and prevention.Lancet. 1999;354(suppl 1):5–10.
Uherek C, Wels W. DNA-carrier proteins for targeted gene delivery.Adv Drug Deliv Rev. 2000;44(2–3):153–166.
Johnston SA, Talaat AM, McGuire MJ. Genetic Immunization What's in a Name?Arch Med Res. 2002;33:325–329.
Denny WA. Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy).J Biomed Biotechnol. 2003;1:48–70.
Denny WA, Wilson WR. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies.J Pharm Pharmacol 1998;50:387–394.
Connors TA. The choice of prodrugs for gene directed enzyme produrg therapy of cancer.Gene Ther 1995;2:702–709.
Bentires-Alj M, Hellin A-C, Lechanteur C, et al. Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis.Cancer Gene Ther. 2000;7:20–26.
Fitzsimons HL, Bland RJ, During MJ. Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain.Methods. 2002;28(2):227–236.
Walther W, Stein U. Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting.Journal of Molecular Medicine (Berlin). 1996;74:379–392.
Qin L, Ding Y, Pahud DR, Chang E, Imperiale MJ, Bromberg JS. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression.Hum Gene Ther. 1997;8:2019–2029.
Paillard F. Promoter attenuation in gene therapy: causes and remedies.Hum Gene Ther. 1997;8:2009–2010.
Weeratna RD, Wu T, Etler SM, Zhang L, Davis HL. Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters.Gene Ther. 2001;8:1872–1878.
Greco O, Marples B, Dachs GU, Williams KJ, Patterson AV, Scott SD. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation.Gene Ther 2002;9:1403–1411.
Anderson WF. Human gene therapy.Nature (London). 1998;392(suppl 6679):25–30.
China OKs Gene Therapy Drug.Genetic Engineering News. 2003: 6.
Galanis E, Russell S. Cancer gene therapy clinical trials: lessons for the future.Br J Cancer 2001;85:1432–1436.
Mulherkar R. Gene therapy for cancer.Curr Sci. 2001;81:555–560.
Baekelandt V, De Strooper B, Nuttin B, Debyser Z. Gene therapeutic strategies for neurodegenerative diseases.Curr Opin Mol Ther. 2000;2:540–554.
Bunnell BA, Morgan RA. Gene therapy for HIV infection.Drugs Today 1996;32:209–224.
Horner AA, Van Uden JH, Zubeldia JM, Broide D, Raz E. DNA-based immunotherapeutics for the treatment of allergic disease.Immunol Rev. 2001;179:102–118.
Crooke ST. Molecular mechanisms of antisense drugs: human RNase H.Antisense Nucleic Acid Drug Dev 1999;9:377–379.
Engels JW, Uhlmann E. Chemistry of Oligonucleotides. In: Malvy C, ed.Pharmaceutical Aspects of Oligonucleotides. London, UK: Taylor & Francis Ltd; 2000;35–78.
Khatsenko O, Morgan R, Truong L, et al. Absorption of antisense oligonucleotides in rat intestine: effect of chemistry and length.Antisense Nucleic Acid Drug Dev 2000;10:35–44.
Stein CA, Subasinghe C, Shinozuka K, Cohen JS. Physicochemical properties of phosphorothioate oligodeoxynucleotides.Nucleic Acids Res. 1988;16:3209–3221.
Matteucci M. Structural modifications toward improved antisense oligonucleotides.Perspectives in Drug Discovery and Design. 1996;4(Antisense Therapeutics):1–16.
Shoji Y, Akhtar S, Periasamy A, Herman B, Juliano RL. Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages.Nucleic Acids Res. 1991;19:5543–5550.
Akhtar S. Antisense technology: selection and delivery of optimally acting antisense oligonucleotides.J Drug Target. 1998;5:225–234.
Smith L, Andersen KB, Hovgaard L, Jaroszewski JW. Rational selection of antisense oligonucleotide sequences.Eur J Pharm Sci. 2000;11:191–198.
Patil SD, Rhodes DG. Influence of divalent cations on the conformation of phosphorothioate oligodeoxynucleotides: a circular dichroism study.Nucleic Acids Res. 2000;28:2439–2445.
Agrawal S, Tan W, Cai Q, Xie X, Zhang R. In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines.Antisense Nucleic Acid Drug Dev 1997;7:245–249.
Akhtar S, Hughes MD, Khan A, et al. The delivery of antisense therapeutics.Adv Drug Deliv Rev. 2000;44:3–21.
Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer.Adv Drug Deliv Rev. 2002;54:715–758.
Aigner A, Juhl H, Malerczyk C, Tkybusch A, Benz CC, Czubayko F. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumor cell proliferation.Oncogene. 2001;20:2101–2111.
Zhang L, Gasper WJ, Stass SA, Ioffe OB, Davis MA, Mixson AJ. Angiogenic inhibition mediated by a DNA zyme that targets vascular endothelial growth factor receptor 2.Cancer Res 2002;62:5463–5469.
Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics.Clin Chem. 1999;45(9):1628–1650.
de Soultrait VR, Lozach P-Y, Altmeyer R, Tarrago-Litvak L, Litvak S, Andreola ML. DNA aptamers derived from HIV-I RNase H inhibitors are strong anti-integrase agents.J Mol Biol. 2002;324:195–203.
Chaloin L, Lehmann MJ, Sczakiel G, Restle T. Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1.Nucleic Acids Res. 2002;30:4001–4008.
Bertrand J-R, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo.Biochem Biophys Res Commun. 2002;296:1000–1004.
McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs.Nat Rev Genet. 2002;3:737–747.
Scherr M, Morgan MA, Eder M. Gene silencing mediated by small interfering RNAs in mammalian cells.Curr Med Chem. 2003;10:245–256.
Kurreck J. Antisense technologies: improvement through movel chemical modifications.Eur J Biochem. 2003;270:1628–1644.
Martinez MA, Gutierrez A, Armand-Ugon M, et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication.AIDS. 2002;16(18):2385–2390.
Ge Q, McManus MT, Nguyen T, et al. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription.Proc Natl Acad Sci USA. 2003;100:2718–2723.
Bennett RM. As nature intended? The uptake of DNA and oligonucleotides by eukaryotic cells.Antisense Res Dev. 1993;3:235–241.
Le Doan T. Cell binding and internalisation of oligonucleotides.S.T.P. Pharma Sciences. 2001;11:75–82.
Hughes MD, Hussain M, Nawaz Q, Sayyed P, Akhtar S. The cellular delivery of antisense oligonucleotides and ribozymes.Drug Discov Today. 2001;6:303–315.
Liu F, Huang L. Development of non-viral vectors for systemic gene delivery.J Control Release. 2002;78(1–3):259–266.
Akhtar S, Juliano RL. Cellular uptake and intracellular fate of antisense oligonucleotides.Trends Cell Biol. 1992;2:139–144.
Wu-Pong S. Alternative interpretations of the oligonucleotide transport literature: insights from nature.Adv Drug Deliv Rev. 2000;44:59–70.
Holmes AR, Dohrman AF, Ellison AR, Gonez KK, Gruenert DC. Intracellular compartmentalization of DNA fragments in cultured airway epithelial cells mediated by cationic lipids.Pharm Res. 1999;16:1020–1025.
Kamiya H, Tsuchiya H, Yamazaki J, Harashima H. Intracellular trafficking and transgene expression of viral and non-viral gene vectors.Adv Drug Deliv Rev. 2001;52:153–164.
Tachibana R, Harashima H, Shinohara Y, Kiwada H. Quantitative studies on the nuclear transport of plasmid DNA and gene expression employing nonviral vectors.Adv Drug Deliv Rev. 2001;52:219–226.
Brown MD, Schatzlein AG, Uchegbu IF. Gene delivery with synthetic (non viral) carriers.Int J Pharm. 2001;229(1–2):1–21.
Agrawal S, Zhang R. Pharmacokinetics of oligonucleotides.Ciba Foundation Symposium. 1997;209(Oligonucleotides as Therapeutic Agents):60–78.
Yu RZ, Geary RS, Leeds JM, et al. Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of ha-ras encapsulated in stealth liposomes.Pharm Res. 1999;16:1309–1315.
Tam P, Monck M, Lee D, et al. Stabilized plasmid-lipid particles for systemic gene therapy.Gene Ther. 2000;7:1867–1874.
Kunisawa J, Nakagawa S, Mayumi T. Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development.Adv Drug Deliv Rev. 2001;52:177–186.
Hope MJ, Mui B, Ansell S, Ahkong QF. Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs.Mol Membr Biol.. 1998;15:1–14.
Jaaskelainen I, Moenkkoenen J, Urtti A. Oligonucleotide-cationic liposome interactions. A physicochemical study.Biochim Biophys Acta. 1994;1195:115–123.
Jaaskelainen I, Sternberg B, Monkkonen J, Urtti A. Physicochemical and morphological properties of complexes made of cationic liposomes and oligonucleotides.Int J Pharm. 1998; 167(1–2):191–203.
Monnard P-A, Oberholzer T, Luisi P. Entrapment of nucleic acids in liposomes.Biochim Biophys Acta. 1997;1329:39–50.
McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles for gene and drug delivery.Annu Rev Biomed Eng. 2000;2:289–313.
Regnier V, Tahiri A, Andre N, Lemaitre M, Le Doan T, Preat V. Electroporation-mediated delivery of 3′-protected phosphodiester oligodeoxynucleotides to the skin.J Control Release. 2000;67(2–3):337–346.
Huang L, Viroonchatapan E. Introduction. In: Huang L, Hung M-C, Wagner E, ed.Nonviral Vectors for Gene Therapy. San Diego, CA: Academic Press; 1999:3–22.
Lotze MT, Kost TA. Viruses as gene delivery vectors: application to gene function, target validation, and assay development.Cancer Gene Ther. 2002;9:692–699.
Galimi F, Verma IM. Opportunities for the use of lentiviral vectors in human gene therapy.Curr Top Microbiol Immunol. 2002;261:245–254.
Martin KR, Klein RL, Quigley HA. Gene delivery to the eye using adeno-associated viral vectors.Methods. 2002;28(2):267–275.
Lien Y-HH, Lai L-W. Gene therapy for renal disorders: what are the benefits for the elderly?.Drugs Aging.. 2002;19:553–560.
Wolf JK, Jenkins AD. Gene therapy for ovarian cancer (review).Int J Oncol. 2002;21:461–468.
Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases.Drugs. 2000;60:249–271.
Lever AML. Gene therapy in the fight against AIDS.Expert Opinion on Therapeutic Patents. 1996;6:161–167.
Zhao W, Kobayashi M, Hosokawa M, Seth P. Adenoviral vectors for cancer gene therapy.Curr Genomics. 2002;3:163–180.
Hale SJ, Green NK. Viral approaches to cancer gene therapy.Expert Opinion on Therapeutic Patents. 2002;12:369–378.
Garton KJ, Ferri N, Raines EW. Efficient expression of exogenous genes in primary vascular cells using IRES-based retroviral vectors.Biotechniques. 2002;32(4):830,832,834,836,838,840,842–843.
Heider H, Verca SB, Rusconi S, Asmis R. Comparison of lipid-mediated and adenoviral gene transfer in human monocyte-derived macrophages and COS-7 cells.Biotechniques. 2000;28(2):260–265, 268–270.
Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics.Nat Med. 2001;7:33–40.
Favre D, Provost N, Blouin V, et al. Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle.Mol Ther. 2001;4:559–566.
Timme TL, Hall SJ, Barrios R, Woo SLC, Aguilar-Cordova E, Thompson TC. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice.Cancer Gene Ther. 1998;5:74–82.
Arruda VR, Fields PA, Milner R, et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males.Mol Ther. 2001;4:586–592.
Tenenbaum L, Lehtonen E, Monahan PE. Evaluation of risks related to the use of adeno-associated virus-based vectors.Curr Gene Ther. 2003;3:545–565.
Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer.Mol Genet Metab. 2003;80(1–2):148–158.
Owens RA. Second generation adeno-associated virus type 2-based gene therapy systems with the potential for preferential integration into AAVSI.Curr Gene Ther. 2002;2:145–159.
Nyberg-Hoffman C, Aguilar-Cordova E. Instability of adenoviral vectors during transport and its implication for clinical studies.Nat Med. 1999;5:955–957.
Cao B, Mytinger JR, Huard J. Adenovirus mediated gene transfer to skeletal muscle.Microsc Res Tech. 2002;58:45–51.
Bachrach E, Pelegrin M, Piechaczyk M, Pedersen FS, Duch M. Efficient Gene Transfer into Spleen Cells of Newborn Mice by a Replication-Competent Retroviral Vector.Virology. 2002;293:328–334.
Fattal E, Delattre J, Dubernet C, Couvreur P. Liposomes for the delivery of nucleotides and oligonucleotides.S.T.P. Pharma Sciences. 1999;9:383–390.
Fattal E, Dubernet C, Couvreur P. Liposome-based formulations for the delivery of oligonucleotides.S.T.P. Pharma Sciences. 2001;11:31–44.
Pedroso de Lima MC, Simoes S, Pires P, Faneca H, Duzgunes N. Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications.Adv Drug Deliv Rev. 2001;47(2–3):277–294.
Hwang SJ, Davis ME. Cationic polymers for gene delivery: designs for overcoming barriers to systemic administration.Curr Opin Mol Ther. 2001;3:183–191.
Lemkine GF, Demeneix BA. Polyethylenimines for in vivo gene delivery.Curr Opin Mol Ther. 2001;3:178–182.
Lollo CP, Banaszezyk MG, Mullen PM, et al. Poly-L-lysine-based gene delivery systems: synthesis, purification, and application.Methods Mol Med. 2002;69:1–13.
LeHoux JG, Grondin F. Some effects of chitosan on liver function in the rat.Endocrinology. 1993;132:1078–1084.
Florea BI, Meaney C, Junginger HE, Borchard G. Transfection efficiency and toxicity of polyethylenimine in differentiated Calu-3 and non-differentiated COS-1 cell cultures.AAPS Pharm Sci. 2002;4(3):E12.
Koping-Hoggard M, Tubulekas I, Guan H, et al. Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo.Gene Ther. 2001;8:1108–1121.
Godbey WT, Mikos AG. Recent progress in gene delivery using non-viral transfer complexes.J Control Release. 2001;72(1–3):115–125.
Petersen H, Fechner PM, Fischer D, Kissel T. Synthesis, characterization, and biocompatibility of polyethylenimine-graft-poly(ethylene glycol) block copolymers.Macromolecules. 2002;35:6867–6874.
Leclercq F, Dubertret C, Pitard B, Scherman D, Herscovici J. Synthesis of glycosylated polyethylenimine with reduced toxicity and high transfecting efficiency.Bioorg Med Chem Lett. 2000;10:1233–1235.
Akinc A, Langer R. Measuring the pH environment of DNA delivered using nonviral vectors: implications for lysosomal trafficking.Biotechnol Bioeng. 2002;78:503–508.
Mumper RJ, Klakamp SL. Polymeric gene delivery systems for in vivo gene therapy.Drug Targeting and Delivery. 1999;10(Advanced Gene Delivery):143–173.
Ward CM, Pechar M, Oupicky D, Ulbrich K, Seymour LW. Modification of pLL/DNA complexes with a multivalent hydrophilic polymer permits folate-mediated targeting in vitro and prolonged plasma circulation in vivo.J Gene Med. 2002;4:536–547.
Jeong JH, Park TG. Poly(l-lysine)-g-poly(d,l-lactic-co-glycolic acid) micelles for low cytotoxic biodegradable gene delivery carriers.J Control Release. 2002;82:159–166.
Wolfert MA, Seymour LW. Chloroquine and amphipathic peptide helixes show synergistic transfection in vitro.Gene Ther. 1998;5:409–414.
Singla AK, Chawla M. Chitosan: some pharmaceutical and biological aspects-an update.J Pharm Pharmacol. 2001;53:1047–1067.
Kawamata Y, Nagayama Y, Nakao K, et al. Receptor-independent augmentation of adenovirus-mediated gene transfer with chitosan in vitro.Biomaterials. 2002;23:4573–4579.
Cui Z, Mumper RJ. Chitosan-based nanoparticles for topical genetic immunization.J Control Release. 2001;75:409–419.
Roy K, Mao H-Q, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunological protection in a murine model of peanut allergy.Nat Med. 1999;5:387–391.
Gitsov I, Lambrych KR. Dendrimers: synthesis and applications.Microspheres, Microcapsules & Liposomes. 2002;5(Dendrimers, Assemblies, Nanocomposites):31–68.
Eichman JD, Bielinska AU, Kukowska-Latallo JF, Baker JR, Jr. The use of PAMAM dendrimers in the efficient transfer of genetic material into cells.Pharm Sci Technol Today. 2000;3:232–245.
Zinselmeyer BH, Mackay SP, Schatzlein AG, Uchegbu IF. The lower-generation polypropylenimine dendrimers are effective gene-transfer agents.Pharm Res. 2002;19:960–967.
Yoo H, Juliano RL. Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers.Nucleic Acids Res. 2000;28:4225–4231.
Tejada-Berges T, Granai CO, Gordinier M, Gajewski W. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer.Expert Rev Anticancer Ther. 2002;2:143–150.
Marshall J, Yew NS, Eastman SJ, Jiang C, Scheule RK, Cheng SH. Cationic lipid-mediated gene delivery to the airways. In: Wagner E, ed.Nonviral Vectors for Gene Therapy. San Diego, CA: Academic Press; 1999;39–68.
Felgner JH, Kumar R, Sridhar CN, et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations.J Biol Chem. 1994;269:2550–2561.
Hofland HEJ, Shephard L, Sullivan SM. Formation of stable cationic lipid/DNA complexes for gene transfer.Proc Natl Acad Sci USA. 1996;93:7305–7309.
Kang S-H, Zirbes EL, Kole R. Delivery of antisense oligonucleotides and plasmid DNA with various carrier agents.Antisense Nucleic Acid Drug Dev. 1999;9:497–505.
Lappalainen K, Jaaskelainen I, Syrjanen K, Urtti A, Syrjanen S. Comparison of cell proliferation and toxicity assays using two cationic liposomes.Pharm Res. 1994;11:1127–1131.
Patil SD, Rhodes DG, Burgess DJ. Anionic liposomal delivery system for DNA transfection.The AAPS Journal. 2004;6:E29.
Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes.Pharm Res. 2000;17:521–525.
Filion MC, Phillips NC. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells.Biochim Biophys Acta. 1997;1329:345–356.
Freimark BD, Blezinger HP, Florack VJ, et al. Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes.J Immunol. 1998;160:4580–4586.
Lee H, Williams SKR, Allison SD, Anchordoquy TJ. Analysis of self-assembled cationic lipid-DNA gene carrier complexes using flow field-flow fractionation and light scattering.Anal Chem. 2001;73:837–843.
Audouy S, Molema G, De Leij L, Hoekstra D. Serum as a modulator of lipoplex-mediated gene transfection: dependence of amphiphile, cell type and complex stability.J Gene Med. 2000;2:465–476.
Liu F, Qi H, Huang L, Liu D. Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration.Gene Ther. 1997;4:517–523.
Wheeler CJ, Felgner PL, Tsai YJ, et al. A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung.Proc Natl Acad Sci USA. 1996;93:11454–11459.
Fillion P, Desjardins A, Sayasith K, Lagace J. Encapsulation of DNA in negatively charged liposomes and inhibition of bacterial gene expression with fluid liposome-encapsulated antisense oligonucleotides.Biochim Biophys Acta. 2001;1515:44–54.
Lakkaraju A, Dubinsky JM, Low WC, Rahman Y-E. Neurons are protected from excitotoxic death by p53 antisense oligonucleotides delivered in anionic liposomes.J Biol Chem. 2001;276:32000–32007.
Patil SD, Rhodes DG. Conformation of oligodeoxynucleotides associated with anionic liposomes.Nucleic Acids Res. 2000;28:4125–4129.
Patil SD, Rhodes DG, Burgess DJ. Biophysical characterization of anionic lipoplexesBiochim Biophys Acta.-Biomembranes. 2005; In Press.
Lee RJ, Huang L. Lipidic vector systems for gene transfer.Crit Rev Ther Drug Carrier Syst. 1997;14:173–206.
Guo W, Gosselin MA, Lee RJ. Characterization of a novel diolein-based LPDII vector for gene delivery.J Control Release. 2002;83:121–132.
Perrie Y, Gregoriadis G. Liposome-entrapped plasmid DNA: characterization studies.Biochim Biophys Acta. 2000;1475:125–132.
Venugopalan P, Jain S, Sankar S, Singh P, Rawat A, Vyas SP. pH-Sensitive liposomes: mechanism of triggered release to drug and gene delivery prospects.Pharmazie. 2002;57:659–671.
Maclean AL, Symonds G, Ward R. Immunoliposomes as targeted delivery vehicles for cancer therapeutics (Review).Int J Oncol. 1997;11:325–332.
Legendre JY, Szoka FC Jr. Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes.Pharm Res. 1992;9:1235–1242.
Reddy JA, Low PS. Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation.J Control Release. 2000;64(1–3):27–37.
Sviridov YV, Zhdanov RI, Podobed OV, Tsvetkova TA, Konstantinov I, Bogdanenko EV. The LacZ gene transfer into L929 cells and [14C]-DNA tissue distribution following intraperitoneal administration of new pH-sensitive lipoplexes in mice.Cytobios. 2001;106:(suppl 1), 7–14.
Xu L, Huang C-C, Huang W, et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.Mol Cancer Ther. 2002;1:337–346.
Shi N, Zhang Y, Zhu C, Boado RJ, Pardridge WM. Brain-specific expression of an exogenous gene after IV administration.Proc Natl Acad Sci USA. 2001;98:12754–12759.
Khaw BA, da Silva J, Vural I, Narula J, Torchilin VP. Intracytoplasmic gene delivery for in vitro transfection with cytoskeleton-specific immunoliposomes.J Control Release. 2001;75(1–2):199–210.
Krauss WC, Park JW, Kirpotin DB, Hong K, Benz CC. Emerging antibody-based HER2 (ErbB-2/neu) therapeutics.Breast Disease. 2000;11:113–124.